K36 Therapeutics

K36 Therapeutics Creating breakthrough therapies for the unmet medical needs of cancer patients worldwide.

🧬Creating breakthrough therapies for the unmet medical needs of cancer patients worldwide.
🔬Our clinical trial is now open!

Check out K36 CEO Terrence Connolly's conversation with Daniel Levine on The Bio Report podcast: "Stopping Shape-Shiftin...
06/17/2026

Check out K36 CEO Terrence Connolly's conversation with Daniel Levine on The Bio Report podcast: "Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug."

https://lnkd.in/eKhXbGpv

Cancer cells are remarkably adaptable. They can change their identity, evade treatment, and develop resistance over time. At K36, we are pursuing a different approach by targeting NSD2, an epigenetic regulator that helps drive these processes in certain cancers.

In this discussion, Terry shares K36 Therapeutics, Inc.'s vision for translating precision epigenetics into meaningful therapies, including:
· Why NSD2 is emerging as a compelling target across multiple cancers
· How epigenetic mechanisms can influence tumor adaptation and treatment resistance
· Our clinical development efforts in t(4;14) multiple myeloma, NSD2-high cancers, and metastatic castration-resistant prostate cancer
· Building a focused biotechnology company around first-in-class science

We're grateful to Daniel Levine and Levine Media Group for the opportunity to discuss the science, strategy, and potential of targeting NSD2.

Listen here on your favorite Podcast Platform: https://lnkd.in/eKhXbGpv

Apple: https://lnkd.in/e5isjjir

Spotify: https://lnkd.in/eBytXz94

Amazon Music: https://lnkd.in/ehViBH2n

June is Men's Health Month.Life gets busy, and it's easy to put off doctor visits and health screenings. This month is a...
06/16/2026

June is Men's Health Month.

Life gets busy, and it's easy to put off doctor visits and health screenings. This month is a good reminder to check in on your health, schedule recommended screenings, and talk with your healthcare provider about any concerns.

Taking care of your health isn't just for you, it's for the people who count on you.

At K36, we're proud to support men's health awareness.

Did you know that not all multiple myeloma is the same?Cytogenetic testing looks at changes in the chromosomes of myelom...
06/15/2026

Did you know that not all multiple myeloma is the same?

Cytogenetic testing looks at changes in the chromosomes of myeloma cells and can help identify specific subtypes of the disease, including abnormalities such as t(4;14), del(17p), gain(1q), and others. Understanding your cytogenetics can help your healthcare team better understand your disease and discuss treatment options that may be appropriate for you.

If you have multiple myeloma, consider asking your doctor:

• What are my cytogenetic test results?
• Do I have any high-risk features?
• How do my cytogenetics affect my treatment plan?
• Are there clinical trials designed for patients with my specific subtype?

K36 Therapeutics is currently studying KTX-1001 (gintemetostat), an investigational medicine in a clinical trial that includes patients with t(4;14) multiple myeloma, a subtype associated with increased NSD2/MMSET activity.

Every patient's journey is unique. Knowing your cytogenetics is an important step in understanding your disease and exploring all available treatment options, including clinical trials.

Talk with your healthcare team to learn more. Find a research center near you: https://myeloma.sparkcures.com/trial/1334/NCT05651932

The K36 team is in Stockholm for .If you’re attending , let’s connect. We always enjoy meeting investigators, clinicia...
06/12/2026

The K36 team is in Stockholm for .

If you’re attending , let’s connect. We always enjoy meeting investigators, clinicians, patient advocates, and industry colleagues who share a passion for improving outcomes for patients.

📩 [email protected]

;14

What is t(4;14) Multiple Myeloma? And why does it matter?Most people have never heard of t(4;14) but for patients with m...
06/11/2026

What is t(4;14) Multiple Myeloma? And why does it matter?
Most people have never heard of t(4;14) but for patients with multiple myeloma, it can make a big difference.
👉 t(4;14) is a genetic change (translocation) where pieces of chromosome 4 and 14 swap places. This leads to overactivation of genes like NSD2, which can drive cancer growth.
👉 It occurs in about 10–15% of multiple myeloma patients and is often considered a higher-risk subtype, meaning the disease can behave more aggressively.
👉 Even with today’s treatments, patients with t(4;14) may have shorter responses and need new, targeted approaches.
💡 The good news?
Science is catching up. Researchers are now developing therapies that directly target the biology behind this subtype, especially pathways like NSD2.
🎬 If you want a clear, patient-friendly explanation, watch this HealthTree University video:
👉 https://www.youtube.com/watch?v=33vlPP1gSYQ
💬 Why this matters:
Understanding your specific subtype of myeloma can help guide treatment decisions and open the door to clinical trials and precision therapies.
If you or a loved one has multiple myeloma, ask your doctor:
“Do I know my cytogenetics, including t(4;14)?”
Consider Clinical Trial: https://www.k36tx.com/our-clinical-trials

The K36 Therapeutics is looking forward to attending the European Hematology Association ( ) Congress in Stockholm and c...
06/09/2026

The K36 Therapeutics is looking forward to attending the European Hematology Association ( ) Congress in Stockholm and connecting with the global hematology community.

Our K36-MMSET clinical trial evaluating KTX-1001 for patients with relapsed/refractory multiple myeloma is actively enrolling across the United States, Canada, France, and Spain.

We look forward to meeting with investigators, collaborators, patient advocates, and members of the myeloma community as we continue advancing research for patients with t(4;14) multiple myeloma and other NSD2-driven cancers.

If you'll be attending EHA, we'd love to connect. Send us a DM or email message to [email protected] to schedule time to meet.

What if we could target a fundamental mechanism that cancer cells depend on to maintain their identity and survive? Tha...
06/09/2026

What if we could target a fundamental mechanism that cancer cells depend on to maintain their identity and survive? That is the question driving the work at K36 Therapeutics, Inc.

In the latest https://lnkd.in/eFyDWv-d
Drug Discovery World podcast, our CEO Terrence Connolly and CMO Dr. Shinta Cheng discuss how K36 is advancing first-in-class NSD2 inhibitors, including KTX-1001, currently being evaluated in patients with relapsed/refractory multiple myeloma.

The conversation explores:
🔬 Why NSD2 has emerged as an important target in cancer biology
🧬 How epigenetic therapies may help reshape cancer cell behavior
💡 What makes K36's scientific approach different
🚀 The potential to expand this science beyond multiple myeloma into other cancers

We are still in the early chapters of understanding how epigenetic regulation drives cancer. Still, the opportunity to translate these discoveries into meaningful therapies for patients is what inspires our team every day.
A special thank you to Bruno Quinney and the Drug Discovery World team for highlighting the science and vision behind our work.

Check out the Podcast!
https://lnkd.in/eFyDWv-d

On Spotify
https://lnkd.in/e3vW2D3F

On Apple Podcast
https://lnkd.in/eWN7fSGV

🎧 Listen to the episode and let us know: Which emerging area of cancer research do you believe will have the greatest impact over the next decade?

06/08/2026

Do You Have t(4;14) Multiple Myeloma?

A clinical trial is currently enrolling adults with t(4;14) multiple myeloma.

If you know your cytogenetic testing results and have been told you have t(4;14) myeloma, you may qualify to participate in a research study evaluating an investigational treatment.

Speak with your doctor and healthcare team and to find a research center near you, call SparkCures and ask for the MMSET trial to learn more.

📞 888-850-0650
📧 https://sparkcures.pro/trial/1334/NCT05651932/description
Participation is voluntary. Eligibility criteria apply.

06/05/2026

June 7 is National Cancer Survivors Day.

At K36 Therapeutics, we have the privilege of meeting cancer survivors and their families throughout their journey. What stays with us are not the study protocols, lab results, or clinic schedules.

It's the people.

The clinical trial participant who has faithfully completed her medication diary for more than two years. The father who wants to learn everything he can about his disease and treatment options. The grandmother who arrives at each visit with a different grandchild by her side. The research team affectionately calls her "The Entourage."

These are the people we think about today.

Every survivor's story is different. Every milestone matters.
We are grateful to the patients who participate in research, the caregivers who support them, and the physicians, nurses, coordinators, and researchers who work every day to improve the lives of people living with cancer.

We celebrate survivors and the resilience they show every day. We remain committed to advancing research with the hope of creating more moments, more milestones, and more survivor stories in the years ahead.

Happy National Cancer Survivors Day.

Learn more about our clinical trials: https://www.k36tx.com/our-clinical-trials

06/04/2026

🧬 How Does KTX-1001 Work?

Multiple myeloma cells rely on certain signals inside the cell that help them grow, survive, and resist treatment.

KTX-1001 is an investigational medicine designed to block one of these signals, such as H3K36me2. This may help slow cancer growth, reduce treatment resistance, and make myeloma cells easier to target.

Researchers are studying KTX-1001 in clinical trials for relapsed or refractory multiple myeloma.

https://www.k36tx.com/our-clinical-trials

Address

1 Main Street 13Fl
Cambridge, MA
02142

Website

Alerts

Be the first to know and let us send you an email when K36 Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category